How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Affinity Chromatography Columns Market
- By Type of Affinity Ligand: Protein A, Protein G, Lectins, Aptamers, Antibodies, Metal Chelates
- By Material of Chromatography Column: Agarose-based, Cellulose-based, Synthetic Polymer-based, Magnetic Beads, Silica-based
- By End-User Industry: Biopharmaceuticals, Research Laboratories, Diagnostics, Food and Beverage, Environmental Testing
- By Application: Protein Purification, Enzyme Isolation, Antibody Purification, Nucleic Acid Purification, Vaccine Production
- By Column Format: Pre-packed Columns, Bulk Media, Disposable Columns, Custom Packed Columns
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Protein A leads By Type of Affinity Ligand at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.185 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.193 →
Full report · locked preview
Everything inside the Affinity Chromatography Columns Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Type of Affinity Ligand 6
Material of Chromatography Column 5
End-User Industry 5
Application 5
Column Format 4
Companies profiled
Cytiva (formerly GE Healthcare Life Sciences)
Thermo Fisher Scientific
Sartorius AG
Merck KGaA (MilliporeSigma)
Bio-Rad Laboratories
Agilent Technologies
Tosoh Corporation
Repligen Corporation
BioVision Inc.
Pall Corporation (a part of Danaher)
Sepax Technologies
BIA Separations
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Cytiva (formerly GE Healthcare Life Sciences)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Merck KGaA (MilliporeSigma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Agilent Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Tosoh Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Repligen Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →BioVision Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Pall Corporation (a part of Danaher)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sepax Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →BIA Separations
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →ChromaCon AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Phenomenex (now part of Danaher)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Hitachi High-Technologies Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,322M by 2033 · 10.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Protein A39.8
- Protein G14.0
- Lectins6.8
- Aptamers12.4
- Antibodies14.0
- Metal Chelates12.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,260M → $2,873M · 10.8%
Europe$878.5M → $1,842M · 9.7%
Asia Pacific$802.1M → $1,757M · 10.3%
Latin America$496.5M → $1,104M · 10.5%
Middle East and Africa$381.9M → $874.0M · 10.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.172026
10.192027
10.192028
10.212029
10.232030
10.242031
10.242032
10.272033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Cytiva (formerly GE Healthcare Life Sciences)29.3
- Thermo Fisher Scientific12.6
- Sartorius AG4.8
- Merck KGaA (MilliporeSigma)6.7
- Bio-Rad Laboratories8.7
- Agilent Technologies9.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Type of Affinity Ligand8.4%
Material of Chromatography Column16.2%
End-User Industry23.1%
Application26.1%
Column Format26.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.0
- Europe21.8
- Asia Pacific20.8
- Latin America13.1
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Cytiva (formerly GE Healthcare Life Sciences) | 75 | 80 | 81 | 76 | 96 | 79 | 81 |
| Thermo Fisher Scientific | 86 | 88 | 75 | 80 | 78 | 71 | 80 |
| Sartorius AG | 67 | 83 | 88 | 67 | 80 | 81 | 78 |
| Merck KGaA (MilliporeSigma) | 66 | 81 | 64 | 70 | 75 | 69 | 71 |
| Bio-Rad Laboratories | 74 | 63 | 68 | 66 | 71 | 62 | 67 |
| Agilent Technologies | 69 | 49 | 54 | 50 | 65 | 70 | 60 |
| Tosoh Corporation | 42 | 48 | 62 | 55 | 55 | 65 | 55 |
| Repligen Corporation | 49 | 43 | 48 | 54 | 44 | 43 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Cytiva (formerly GE Healthcare Life Sciences)
- Thermo Fisher Scientific
- Sartorius AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Cytiva (formerly GE Healthcare Life Sciences) | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Thermo Fisher Scientific | ✓ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Sartorius AG | ◐ | ✓ | ✓ | − | ◐ | ◐ |
| Merck KGaA (MilliporeSigma) | ◐ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Bio-Rad Laboratories | ◐ | − | ◐ | ✓ | − | ◐ |
| Agilent Technologies | − | − | ◐ | ◐ | − | − |
| Tosoh Corporation | − | − | ◐ | ◐ | ◐ | ◐ |
| Repligen Corporation | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Cytiva (formerly GE Healthcare Life Sciences)81
2Thermo Fisher Scientific80
3Sartorius AG78
4Merck KGaA (MilliporeSigma)71
5Bio-Rad Laboratories67
6Agilent Technologies60
7Tosoh Corporation55
8Repligen Corporation47
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Cytiva (formerly GE Healthcare Life Sciences)Thermo Fisher ScientificSartorius AG
Challenger2
Strong scale, closing on the leaders.
Merck KGaA (MilliporeSigma)Bio-Rad Laboratories
Contender1
Focused players with pockets of strength.
Agilent Technologies
Niche2
Specialists in a single segment or region.
Tosoh CorporationRepligen Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Type of Affinity Ligand in North America, then scale across Affinity Chromatography Columns Market — a $213M beachhead inside a $3.43B market.
Beachhead (SOM)$213Mobtainable near-term
Serviceable (SAM)$1.33Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Protein A
Best fit — highest urgency & budget in Type of Affinity Ligand.
Economic buyer76 fit
Protein G
Strong fit — clear ROI and a fast path to value.
End user69 fit
Lectins
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Type of Affinity Ligand in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Material of Chromatography Column & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-User Industry
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel26%
Digital / self-serve23%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Type of Affinity Ligand leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Affinity Chromatography Columns Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified20%
Evaluation14%
Closed-won6%
$8.6KCAC
$46KLTV
5.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Affinity Chromatography Columns Market is a high-growth opportunity — $4.14B by 2033, compounding at 10.0%.
TAM · 2025$1.93Btoday
TAM · 2033$4.14Bforecast
CAGR10.0%2027–2033
Cumulative$26.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.14BTotal addressable market
SAM$1.51BServiceable available market
SOM$314MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.0% CAGR
Demand compounds through 2033, outpacing GDP across Type of Affinity Ligand.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Type of Affinity Ligand moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.14BLarge & growingTAM by 2033 at 10.0% CAGR
$1.51BServiceable nowreachable with today’s model
$314MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.23BBear6.5% CAGR
$4.14BBase10.0% CAGR
$5.30BBull13.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Material of Chromatography Column optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Affinity Chromatography Columns Market — a $7.31B market by 2033. Plan: grow share from 7.0% to 13.7%.
Market size · 2033$7.31Btotal addressable
Market CAGR9.0%2027–2033
Target share13.7%from 7.0% today
Revenue ambition$1.00Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.0% | 13.7% | On track |
| Revenue | $511M | $1.00B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 30.5% | 40.0% | At risk |
| Customer retention | 87.1% | 96.1% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Type of Affinity Ligand
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Material of Chromatography Column capability
A defensible second engine — invest in Material of Chromatography Column to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Type of Affinity Ligand share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Material of Chromatography Column
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $125M capacity & capability investment
- Greenlight bolt-on M&A in Material of Chromatography Column
- Authorise North America expansion plan
- Fund R&D program for Type of Affinity Ligand leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAhead
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Affinity Chromatography Columns Market conversation — a $4.68B market you can size, segment and defend in minutes.
Market size · 2033$4.68Btotal opportunity
Growth6.0%CAGR to 2033
Addressable buyers1,113+accounts in scope
Typical ROI4.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Type of Affinity Ligand
Goal Grow share in Type of Affinity Ligand
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.4×return on cost, year one
< 3 mopayback period
$98K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Cytiva (formerly GE Healthcare Life Sciences)Thermo Fisher ScientificSartorius AGMerck KGaA (MilliporeSigma)Bio-Rad LaboratoriesAgilent TechnologiesTosoh CorporationRepligen Corporation+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Affinity Chromatography Columns Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Affinity Chromatography Columns Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Gluten Allergy Testing Service Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportGlute Hamstring Developer Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportGluteal Implant Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportGlutathione Tablet Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportGlutathione Supplement Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportGlutathione Reductase Testing Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportGlutathione for Injection Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportGlutathione Drugs Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportGlutathione Agarose Resin Market
Market size, share, segmentation and regional forecast.
$920M market · 2025 base year
View reportGlutaraldehyde Disinfectant Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportGlutamic Oxaloacetic Transaminase Test Market
Market size, share, segmentation and regional forecast.
$658M market · 2025 base year
View reportGlutamic Acid Decarboxylase ELISA Test Kit Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.